Archives202520242023202220212020201920182017201620152014201320122011 September 07, 2023Result of retail offer and Director shareholding Read More September 06, 2023Major shareholding from Lanstead Capital via TR1 Read More August 31, 2023Subscriptions to raise £1.35 million; Sharing Agreement; WRAP Retail Offer to raise up to £0.5 million • Related Party Transactions Read More August 31, 2023WRAP Retail Offer for up to £500,000 Read More August 31, 2023INTERIM RESULTS for the six months ended 30 June 2023 Read More August 21, 2023Extension of Warrants in Incanthera plc Read More August 11, 2023Board strengthened Ahead of next phase of company progression Read More July 02, 20232023 Result of Annual General Meeting – All Resolutions Passed Read More June 19, 2023Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting Read More June 16, 2023Immupharma PLC Warrants Outstanding Read More June 06, 2023Notice of AGM & Annual Report & Accounts Read More May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More 12345…22
August 31, 2023Subscriptions to raise £1.35 million; Sharing Agreement; WRAP Retail Offer to raise up to £0.5 million • Related Party Transactions Read More
June 19, 2023Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting Read More
May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More
